Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECODE-CKD
2024-517040-65-02Phase 2Authorised
- Sponsor
- Gentofte Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing dapagliflozin with placebo (2 arms). Primary endpoint: Change in left ventricular mass index at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-517040-65-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517040-65-02.